id: NEW:metabolomic_biomarkers_alcohol_to_alcohol_use_disorder
name: Metabolomic Biomarkers for Alcohol â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:metabolomic_biomarkers_alcohol
  node_name: Metabolomic Biomarkers for Alcohol
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Alcohol consumption produces characteristic changes in metabolite profiles'
- 'Step 2: Metabolomic signatures serve as diagnostic biomarkers for AUD detection'
- 'Step 3: Certain metabolomic patterns indicate risk for alcohol consumption problems'
- 'Step 4: Metabolomic information can identify individuals who may respond to treatment'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'Shaunna L. Clark et al. 2024. "Next-generation biomarkers for alcohol consumption
    and alcohol use disorder diagnosis, prognosis, and treatment: A critical review.." https://doi.org/10.1111/acer.15476'
  supporting_citations:
  - Additional citations require full-text access - this is a critical review summarizing omics-based
    biomarker research
  - Studies on metabolomic information as diagnostic biomarkers for AUD referenced in review
  - Studies on metabolomic information as predictive biomarkers for acamprosate response referenced in
    review
  doi: 10.1111/acer.15476
  citation_verified: true
  needs_manual_review: true
  citation_issues:
  - Primary citation doesn't match verified citation from literature search
last_updated: '2025-12-06'
version: '2.0'
description: 'Metabolomic information serves multiple biomarker functions: diagnostic biomarkers for AUD,
  risk biomarkers for alcohol consumption, and predictive biomarkers for response to acamprosate treatment
  in subjects with AUD.'
structural_competency:
  equity_implications: Metabolomic biomarkers have clinical utility for improving treatment outcomes through
    personalized medicine approaches. From a structural perspective, equitable access to advanced biomarker
    testing and personalized treatment is essential. Healthcare system factors (insurance coverage, treatment
    availability) will determine whether these scientific advances translate to reduced health inequities.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.737751'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
